Magnesium oxide 420 MG Oral Tablet — RxCUI 311430
RxNorm drug concept · Semantic clinical drug
RxCUI 311430
Semantic clinical drug · SCD
● Current RxNorm concept 3 FDA products
3 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI311430
Official nameMagnesium oxide 420 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asmagnesium oxide 420 MG (magnesium 253 MG) Oral Tablet
FDA products mapped3
Package NDCs mapped3
Reported Medicaid activity (SDUD)9,912 prescriptions · 17 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Magnesium Oxide: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- It depends on the product you have. Some magnesium oxide tablets work as an antacid — they help relieve acid indigestion and upset stomach. Other products are sold as a dietary sup...
- What is magnesium oxide actually used for?
- When used as an antacid, you shouldn't use the maximum dose for more than two weeks in a row unless your doctor is guiding you. The magnesium supplement form is meant for daily use...
- Can I take it every day, or is it just for when I have an upset stomach?
🕸️ Concept Web — How Magnesium oxide 420 MG Oral Tablet Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Magnesium oxide 420 MG Oral Tablet
RxCUI 311430 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Magnesium oxide
6582IN
-
Magnesium oxide
-
Dose forms 6
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Magnesium oxide Oral Tablet
372692SCDF -
Magnesium oxide Oral Product
1157504SCDG -
Magnesium oxide Pill
1157505SCDG -
Oral Tablet
317541DF -
Oral Product
1151131DFG -
Pill
1151133DFG
-
Magnesium oxide Oral Tablet
-
Clinical & branded drugs 1
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Magnesium oxide 420 MG
332539SCDC
-
Magnesium oxide 420 MG
Showing up to 8 concepts per family — 8 of 8 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Magnesium oxide 420 MG
SCDC · 332539 -
Magnesium oxide Oral Tablet
SCDF · 372692 -
Magnesium oxide Oral Product
SCDG · 1157504 -
Magnesium oxide Pill
SCDG · 1157505
📦 FDA Products & Package NDCs
3 products · 3 package NDCs
3 package NDCs map to RxCUI 311430 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 00603-0213-21 | 100 TABLET in 1 BOTTLE (0603-0213-21) | Magnesium Oxide | Endo USA | 2020-11-10 |
| 10135-0721-01 | 100 TABLET in 1 BOTTLE (10135-721-01) | magnesium oxide | Marlex Pharmaceuticals Inc. | 2023-11-01 |
| 54738-0974-01 | 100 TABLET in 1 BOTTLE (54738-974-01) | Magnesium Oxide | Richmond Pharmaceuticals, Inc. | 2016-02-01 |
Observed labelers:
Endo USA (1) ·
Marlex Pharmaceuticals Inc. (1) ·
Richmond Pharmaceuticals, Inc. (1)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.